Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences stock popped Wednesday on strong ... Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter.

Transcatheter Aortic Valve Replacement (TAVR ... Edwards’ CEO. Guidance: Edwards Lifesciences expects first quarter 2025 ...

Recent health news highlights include Gilead's upbeat 2025 forecast, Edwards Lifesciences surpassing profit estimates, New ...

EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Edwards Lifesciences finished 2024 with solid fourth ... Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue ...